CPHI & PMEC India 2025 ignites pharma innovation and partnerships
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Subscribe To Our Newsletter & Stay Updated